I don't think it will be bought out right now because it looks as if the FDA is not going to approve Neratinib any time soon -- if at all. Their best bet may be getting approval in Europe -- I think they have filed for approval there. But I don't think anyone will buy them unless it looks like there is a statistical significance over Herceptin. Based on their last data it doesn't seem to be any better.
However, I will say this -- with a short interest of around 28%, if they DO get approval in Europe, that may be enough to cause a short squeeze to $100+ in a couple of days because the float is so small and my guess is that there has been a lot of naked shorting going on here. So if you have bought a small position like I have, it is like a lottery ticket, hoping for some good news. However, the shorts have control over this right now, and if they miss earning on Monday (which is actually irrelevant except for an indicator of how fast they are burning cash), that will cause the stock to drop into the low teens. I am holding my position regardless, realizing that a small loss is probable, but a huge gain is a possibility.